FDA approves ViiV’s novel HIV treatment Rukobia
60% of heavily treatment-experienced patients achieved undetectable viral load after taking the drug
Read More
Tag: Fostemsavir
ViiV Healthcare submits HIV drug fostemsavir in the US
The treatment could offer a new option for patients unable to reach viral supression
Read More
ViiV’s fostemsavir shows promise in ‘heavily pre-treated’ HIV patients
ViiV Healthcare’s first-in-class attachment inhibitor fostemsavir has shown promise as a treatment for heavily pre-treated HIV patients failing on current antiretroviral regimens.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
